Affluent Medical is on fire after the announcements!

(Boursier.com) — Affluent Medical climbs by almost 19% to 1.60 euros this Friday on the Paris stock exchange, while the group presented positive results on the clinical added value of Epygon, its cutting-edge medical device for the replacement of the mitral valve in patients suffering from mitral regurgitation.
An article on the successful first implantation in humans of its Epygon transcatheter mitral valve entitled “A Mono-Leaflet, Low-Profile Transcatheter Mitral Prosthesis – First-in-Human Implantation” was published in the prestigious American journal Journal of the American College of Cardiology: Cardiovascular Interventions.

The first implantation of Epygon was performed in February 2023 via a minimally invasive transcatheter procedure by Professor Stefano Salizzoni, MD, PhD, cardiac surgeon and co-investigator of the Minerva pilot clinical study – and his team, at Molinette Hospital of Health and Science in Turin. The article reviews the procedure and the 6-month follow-up, showing good performance of the prosthesis.

Excellent performance

The patient recently reached 1-year follow-up and transesophageal echocardiographic examination revealed excellent valve performance, with no mitral regurgitation or para-valvular leak.
This promising feedback resonates with the survey of more than 60 interventional cardiologists and cardiac surgeons, of which 70% of interventional cardiologists said they would refer their patients to cardiac surgeons if the Epygon valve were available.

Quoting…

Epygon is the first biomimetic transcatheter mitral valve that mimics the native mitral valve and restores the natural vortex of blood flow in the left ventricle. Its transcatheter implantation makes it a quick and minimally invasive procedure that avoids open heart surgery.

Remember that the market for mitral valve repair surgery is estimated at $1.5 billion in the United States-Europe zone in 2023, with growth of 3.5% per year… Portzamparc welcomes this “excellent new” and is targeting a price of 3.60 euros while still being a buyer on the file.